Breast Cancer Marker Panel for BLBC Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Basal-like breast cancer (BLBC) lacks targeted therapies and there is no clinically useful test to risk-stratify patients, leading to poor prognoses and recurrences within the first five years after diagnosis, with standard treatments failing to differentiate between patients who rapidly fail or remain event-free.
Innovation Solution
A compound risk model is developed using a panel of cancer markers (e.g., MKRN2, RGL2, FGF1, FKBP5, etc.) to stratify patients into low-, medium-, and high-risk groups by assaying expression levels, informing clinical decision-making and guiding alternative therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard anthracycline taxane-based chemotherapy is administered to BLBC patients, then treatment is provided according to current guidelines, but the treatment fails to differentiate between patients who will rapidly fail versus those who will remain event-free for five years or longer
Solution Approach 1:
The patent segments BLBC patients into distinct risk groups (low-risk, intermediate-risk, high-risk) based on gene expression profiles. This segmentation allows clinicians to differentiate between patients who will respond well to standard therapy and those who will rapidly progress, thereby resolving the inability of standard chemotherapy to provide risk stratification information.
Solution Approach 2:
The patent performs preliminary risk assessment through gene expression profiling before initiating standard chemotherapy. By identifying high-risk patients upfront using the multigene assay, clinicians can make informed decisions about alternative treatments or intensified therapy protocols before standard chemotherapy fails, thus preventing the loss of prognostic information.
2Adaptability or versatility
If no BLBC-specific test is available, then standard chemotherapy is used for all patients, but this results in poor prognoses and recurrences within the first five years
Solution Approach 1:
The patent applies local quality by providing customized treatment approaches tailored to each patient's specific risk profile. Low-risk patients receive standard therapy with favorable outcomes, while high-risk patients are identified for alternative or intensified treatments, thereby improving overall survival rates through treatment adaptability.
Solution Approach 2:
The patent changes the parameter of treatment selection from a uniform approach to a risk-stratified approach based on gene expression parameters. This allows the treatment regimen to be adapted according to the patient's molecular profile, improving survival outcomes by matching therapy intensity to disease aggressiveness.
3Measurement precision
If a panel of cancer markers is assayed to stratify patients into risk groups, then accurate identification of high-risk patients is achieved, but this requires additional testing infrastructure and complexity
Solution Approach 1:
The patent develops a multigene assay that can be integrated into existing clinical laboratory infrastructure, making the risk stratification tool universally applicable across different healthcare settings. The assay serves multiple functions: diagnostic, prognostic, and therapeutic guidance, thereby managing complexity through multi-functionality rather than requiring separate specialized systems.
Data Source
AI summary
Provided herein are compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, provided herein are methods of treating basal-like breast cancer based on expression levels of a panel of cancer markers.